sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide

2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide

CAS No.:
1032568-63-0
Catalog Number:
AG0039L7
Molecular Formula:
C23H28N8O4
Molecular Weight:
480.5196
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$140
- +
10mg
98%
1 week
United States
$182
- +
50mg
98%
1 week
United States
$432
- +
100mg
98%
1 week
United States
$682
- +
Product Description
Catalog Number:
AG0039L7
Chemical Name:
2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide
CAS Number:
1032568-63-0
Molecular Formula:
C23H28N8O4
Molecular Weight:
480.5196
MDL Number:
MFCD18633201
IUPAC Name:
2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide
InChI:
InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
InChI Key:
MWYDSXOGIBMAET-UHFFFAOYSA-N
SMILES:
COc1c(OCCCN2CCOCC2)ccc2c1nc(NC(=O)c1cnc(nc1)N)n1c2=NCC1
UNII:
WI6V529FZ9
Properties
Complexity:
974  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
480.223g/mol
Formal Charge:
0
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
480.529g/mol
Monoisotopic Mass:
480.223g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
140A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.3  
Literature
Title Journal
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology 20161001
Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Clinical advances in hematology & oncology : H&O 20140201
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Molecular cancer therapeutics 20131101
Properties